Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Orally active partial D2 agonist may have potential in PD and schizophrenia

Sep. 20, 2000

Almirall Prodesfarma commences launch of new triptan for migraine

Sep. 19, 2000

MetaPhore receives NIH grant for the study of novel pain treatments

Sep. 19, 2000

Research at Sanofi-Synthelabo leads to discovery of promising selective CB1 antagonist

Sep. 19, 2000

SK reveals orally active compounds for depression which inhibit MAO

Sep. 19, 2000

Wyeth-Ayerst obtains Alzheimer's drug discovery-related license

Sep. 19, 2000

Phase II NeuroCell-PD trial for Parkinson's disease extended

Sep. 19, 2000

Aurora Biosciences announces therapeutic drug discovery alliance

Sep. 18, 2000

Preparation and therapeutic use of new neurotrophic agents described in recent patent

Sep. 18, 2000

U. of Toledo describes new class of muscarinic receptor agonists

Sep. 18, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...